FDG PET/CT imaging

DIAGNOSTIC_TEST2 trials

Sponsors

Abramson Cancer Center at Penn Medicine, Turku University Hospital

Conditions

Clinical Stage III Nodal or Intransit Disease or Resectable Stage IV MelanomaHigh Grade Ovarian Serous AdenocarcinomaHigh Grade Serous Carcinoma

Unknown Phase

Early FDG PET in Melanoma

TerminatedNCT02716077

Abramson Cancer Center at Penn MedicineClinical Stage III Nodal or Intransit Disease or Resectable Stage IV Melanoma

Start: 2016-03-31End: 2021-03-31Updated: 2021-07-23

Multi-layer Data to Improve Diagnosis, Predict Therapy Resistance and Suggest Targeted Therapies in HGSOC

RecruitingNCT04846933

Turku University HospitalHigh Grade Ovarian Serous Adenocarcinoma, High Grade Serous Carcinoma

Start: 2012-02-01End: 2029-12-31Target: 200Updated: 2025-01-16

Related Papers

Multi-omics analysis reveals the attenuation of the interferon pathway as a driver of chemo-refractory ovarian cancer.

2025-08-291 citations

Abstract 1257: Response to primary therapy predicts tumor evolution dynamics at relapse in ovarian cancer

Cancer Research2025-04-21

Abstract PR003: DNA methylation reveals metastatic colonization routes in ovarian cancer

Cancer Research2025-02-01

Abstract 4249: Establishment and analysis of patient-derived high-grade serous ovarian cancer organoids for disease modeling and drug testing

Cancer Research2024-03-22

Abstract 4940: Unraveling ctDNA features in high-grade serous ovarian carcinoma and insights from genomic and transcriptomic integration

Cancer Research2024-03-22

Abstract 7014: Integrative DNA methylation cancer profiling reveals patterns associated with tumor progression and treatment response

Cancer Research2024-03-22

Abstract 1617: Tumor evolution during therapy in ovarian cancer

Cancer Research2024-03-22

Abstract B102: Mutational and copy number-based ctDNA profiles mirror high-grade serous cancer tumors and enable detection of genetic changes appearing at recurrence

Cancer Research2024-03-041 citations

Abstract A003: Characterizing DNA methylation patterns driving chemotherapy resistance in ovarian high-grade serous carcinoma

Cancer Research2024-03-04

Abstract A027: Genome-wide quantification of copy-number aberration impact on gene expression in ovarian high-grade serous carcinoma

Cancer Research2024-03-04

Abstract B027: Screening of drug candidates to repurpose for high-grade serous ovarian cancer treatment

Cancer Research2024-03-04